Licensing opportunity
Scientists at the Friedrich Miescher Institute for Biomedical Research, which is part of the Novartis Research Foundation, have discovered that lymphoma development due to aberrant expression of two kinases, NDR1 and/or NDR2, is late onset.
This suggests that early detection of aberrant NDR1 and/or NDR2 expression may allow for treatment before the disease progresses. The finding could also be applied to screening for anti-cancer drugs.
A patent is pending and the rights are available for exclusive or non-exclusive licence.
Receive the Funding Newswire [full access requires a subscription] each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening. 
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.
